MOLECULAR BIOLOGY AND DRUG THERAPIES OF CHRONIC MYELOID LEUKEMIA: A REVIEW OF RECENT LITERATURE
Background: Chronic myeloid leukaemia (CML) is a clonal myeloproliferative disorder of blood stem cells, which is typically characterized by the presence of a Philadelphia chromosome. Even though there have been several studies on the molecular genetics, pharmacogenomics, pharmacological treatments...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Superior University Lahore, Pakistan
2024-03-01
|
| Series: | International Journal of Pharmacy & Integrated Health Sciences |
| Subjects: | |
| Online Access: | https://ijpihs.pk/index.php/IJPIHS/article/view/121 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1839640772757946368 |
|---|---|
| author | Sameen Shahid Muhammad Farooq Sabar Zafar Iqbal Muhammad Zafar Saleem Muhammad Abbas Khokhar Sana Ashiq |
| author_facet | Sameen Shahid Muhammad Farooq Sabar Zafar Iqbal Muhammad Zafar Saleem Muhammad Abbas Khokhar Sana Ashiq |
| author_sort | Sameen Shahid |
| collection | DOAJ |
| description |
Background: Chronic myeloid leukaemia (CML) is a clonal myeloproliferative disorder of blood stem cells, which is typically characterized by the presence of a Philadelphia chromosome. Even though there have been several studies on the molecular genetics, pharmacogenomics, pharmacological treatments for CML, and its mechanism is still not fully understood. Objectives: This study is designed to provide new updates and better insights into CML molecular biology and drug therapy, along with their benefits and drawbacks. Methodology: For this review, the recent literature was searched from January 2019 to 2023 through various electronic databases. Results: Review findings further suggested that imatinib mesylate was the first tyrosine kinase inhibitor (TKI) licensed as first-line therapy for affected people with CML in the chronic, blast, and rapid phases. Dasatinib is another second-generation multi-target kinase inhibitor, for imatinib-resistant CML treatment in all stages, which is 325 times more effective than imatinib and 16-fold more effective than nilotinib. Nilotinib received approval from the Food and Drug Administration (FDA) for handling imatinib-resistant patients. Bosutinib and ponatinib are other renowned TKIs taken orally. European Medicine Agency (EMA) and FDA-approved asciminib in moderate to severe, rapid, and blast-phase CML patients intolerant to previous therapies. Conclusion: In conclusion, this study indicated the need to include advanced computational tools in addition to the large sample size of cohort studies, which may result in a better understanding of pathophysiology and better clinical outcomes.
|
| format | Article |
| id | doaj-art-8c189edab39a4ac5a7a22c76e7d190d3 |
| institution | Matheson Library |
| issn | 2958-1656 2789-2840 |
| language | English |
| publishDate | 2024-03-01 |
| publisher | Superior University Lahore, Pakistan |
| record_format | Article |
| series | International Journal of Pharmacy & Integrated Health Sciences |
| spelling | doaj-art-8c189edab39a4ac5a7a22c76e7d190d32025-07-03T07:55:59ZengSuperior University Lahore, PakistanInternational Journal of Pharmacy & Integrated Health Sciences2958-16562789-28402024-03-015110.56536/ijpihs.v5i1.121MOLECULAR BIOLOGY AND DRUG THERAPIES OF CHRONIC MYELOID LEUKEMIA: A REVIEW OF RECENT LITERATURESameen Shahid0Muhammad Farooq Sabar1Zafar Iqbal2Muhammad Zafar Saleem3Muhammad Abbas Khokhar4Sana Ashiq5Centre for Applied Molecular Biology, University of the Punjab, Lahore, PakistanCentre for Applied Molecular Biology, University of the Punjab, Lahore-PakistanCollege of Applied Medical Sciences (CoAMS) King Saud Bin Abdulaziz. University of Health Sciences. Centre for Applied Molecular Biology, University of the Punjab, Lahore, PakistanKing Edward Medical College, Mayo Hospital Lahore, Punjab, Pakistan.Centre for Applied Molecular Biology, University of the Punjab, Lahore, Pakistan Background: Chronic myeloid leukaemia (CML) is a clonal myeloproliferative disorder of blood stem cells, which is typically characterized by the presence of a Philadelphia chromosome. Even though there have been several studies on the molecular genetics, pharmacogenomics, pharmacological treatments for CML, and its mechanism is still not fully understood. Objectives: This study is designed to provide new updates and better insights into CML molecular biology and drug therapy, along with their benefits and drawbacks. Methodology: For this review, the recent literature was searched from January 2019 to 2023 through various electronic databases. Results: Review findings further suggested that imatinib mesylate was the first tyrosine kinase inhibitor (TKI) licensed as first-line therapy for affected people with CML in the chronic, blast, and rapid phases. Dasatinib is another second-generation multi-target kinase inhibitor, for imatinib-resistant CML treatment in all stages, which is 325 times more effective than imatinib and 16-fold more effective than nilotinib. Nilotinib received approval from the Food and Drug Administration (FDA) for handling imatinib-resistant patients. Bosutinib and ponatinib are other renowned TKIs taken orally. European Medicine Agency (EMA) and FDA-approved asciminib in moderate to severe, rapid, and blast-phase CML patients intolerant to previous therapies. Conclusion: In conclusion, this study indicated the need to include advanced computational tools in addition to the large sample size of cohort studies, which may result in a better understanding of pathophysiology and better clinical outcomes. https://ijpihs.pk/index.php/IJPIHS/article/view/121CMLDrug TherapiesTKIsMolecular Biology |
| spellingShingle | Sameen Shahid Muhammad Farooq Sabar Zafar Iqbal Muhammad Zafar Saleem Muhammad Abbas Khokhar Sana Ashiq MOLECULAR BIOLOGY AND DRUG THERAPIES OF CHRONIC MYELOID LEUKEMIA: A REVIEW OF RECENT LITERATURE International Journal of Pharmacy & Integrated Health Sciences CML Drug Therapies TKIs Molecular Biology |
| title | MOLECULAR BIOLOGY AND DRUG THERAPIES OF CHRONIC MYELOID LEUKEMIA: A REVIEW OF RECENT LITERATURE |
| title_full | MOLECULAR BIOLOGY AND DRUG THERAPIES OF CHRONIC MYELOID LEUKEMIA: A REVIEW OF RECENT LITERATURE |
| title_fullStr | MOLECULAR BIOLOGY AND DRUG THERAPIES OF CHRONIC MYELOID LEUKEMIA: A REVIEW OF RECENT LITERATURE |
| title_full_unstemmed | MOLECULAR BIOLOGY AND DRUG THERAPIES OF CHRONIC MYELOID LEUKEMIA: A REVIEW OF RECENT LITERATURE |
| title_short | MOLECULAR BIOLOGY AND DRUG THERAPIES OF CHRONIC MYELOID LEUKEMIA: A REVIEW OF RECENT LITERATURE |
| title_sort | molecular biology and drug therapies of chronic myeloid leukemia a review of recent literature |
| topic | CML Drug Therapies TKIs Molecular Biology |
| url | https://ijpihs.pk/index.php/IJPIHS/article/view/121 |
| work_keys_str_mv | AT sameenshahid molecularbiologyanddrugtherapiesofchronicmyeloidleukemiaareviewofrecentliterature AT muhammadfarooqsabar molecularbiologyanddrugtherapiesofchronicmyeloidleukemiaareviewofrecentliterature AT zafariqbal molecularbiologyanddrugtherapiesofchronicmyeloidleukemiaareviewofrecentliterature AT muhammadzafarsaleem molecularbiologyanddrugtherapiesofchronicmyeloidleukemiaareviewofrecentliterature AT muhammadabbaskhokhar molecularbiologyanddrugtherapiesofchronicmyeloidleukemiaareviewofrecentliterature AT sanaashiq molecularbiologyanddrugtherapiesofchronicmyeloidleukemiaareviewofrecentliterature |